Novo Nordisk A/S Q2 2025 Earnings Report

Novo Nordisk A/S EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.89
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Novo Nordisk A/S Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $77.51 billion
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Novo Nordisk A/S Announcement Details

• Quarter: Q2 2025
• Date: 8/6/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, August 6, 2025
• Conference Call Time: 7:00AM ET

Novo Nordisk A/S (NYSE:NVO), together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.